Hepatocellular carcinoma: guideline history

No version history recorded yet for this cancer; the concordance rows below compare what each body says today.

Current positions

Only where bodies disagree1 of 1 settings


Hepatocellular carcinoma · Unresectable, first line Atezolizumab plus bevacizumab (IMbrave150) Atezolizumab Bevacizumab IMbrave150	Preferred Category 1, preferred 2020-06	Recommended I, A; ESMO-MCBS 4 2021	Recommended TA666 2020-12	·	Bodies agree

Other cancers

Acute myeloid leukaemia Bladder & urothelial cancer Cervical cancer Chronic lymphocytic leukaemia Colorectal cancer Diffuse large B-cell lymphoma Endometrial cancer Gastric & gastro-oesophageal junction cancer HER2-positive breast cancer HR-positive / HER2-negative breast cancer Melanoma Multiple myeloma Non-small-cell lung cancer Oesophageal cancer Ovarian cancer Prostate cancer Renal cell carcinoma Triple-negative breast cancer (TNBC)

Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.